A Phase IIa Randomized, Double-Blind, Placebo Controlled Studyto Evaluate the Effects of Odanacatib (MK-0822) on Bone MineralDensity (BMD) and Overall Safety in the Treatment of Osteoporosisin Postmenopausal Women Previously Treated withAlendronate

Merck Co Inc0 个研究点目标入组 247 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Inclusion Criteria:
•1. Patient has been postmenopausal for at least 5 years
•2. Patient has taken or is taking alendronate
•3. Patient agrees not to use medications for osteoporosis other than what is provided by the study

•Exclusion Criteria:
•Patient has a history or evidence of hip fracture
•Patient has a history of cancer within 5 years of screening, except certain skin or cervical cancers.
•Patient has active parathyroid disease
•Patient has a history of thyroid disease not adequately controlled by medication
•Patient is taking anti-seizure medication and has abnormal calcium metabolism
•Patient has received any bisphosphonate other than alendronate for 20% of the last 3 years, or within 3 months of screening

发起方